Premium
Antitubercular and Antibacterial Activity of Quinonoid Natural Products Against Multi‐Drug Resistant Clinical Isolates
Author(s) -
Dey Diganta,
Ray Ratnamala,
Hazra Banasri
Publication year - 2014
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.5090
Subject(s) - plumbagin , thymoquinone , antimycobacterial , emodin , menadione , microbiology and biotechnology , antimicrobial , mycobacterium tuberculosis , antibiotics , antibacterial activity , tuberculosis , drug , antibacterial agent , biology , pharmacology , medicine , bacteria , enzyme , biochemistry , genetics , pathology , antioxidant
Multi‐drug resistant Mycobacterium tuberculosis and other bacterial pathogens represent a major threat to human health. In view of the critical need to augment the current drug regime, we have investigated therapeutic potential of five quinonoids, viz. emodin, diospyrin, plumbagin, menadione and thymoquinone, derived from natural products. The antimicrobial activity of quinonoids was evaluated against a broad panel of multi‐drug and extensively drug‐resistant tuberculosis (M/XDR‐TB) strains, rapid growing mycobacteria and other bacterial isolates, some of which were producers of β‐lactamase, Extended‐spectrum β‐lactamase (ESBL), AmpC β‐lactamase, metallo‐beta‐lactamase (MBL) enzymes, as well as their drug‐sensitive ATCC counterparts. All the tested quinones exhibited antimycobacterial and broad spectrum antibacterial activity, particularly against M. tuberculosis (lowest MIC 0.25 µg/mL) and Gram‐positive bacteria (lowest MIC <4 µg/mL) of clinical origin. The order of antitubercular activity of the tested quinonoids was plumbagin > emodin ~ menadione ~ thymoquinone > diospyrin, whereas their antibacterial efficacy was plumbagin > menadione ~ thymoquinone > diospyrin > emodin. Furthermore, this is the first evaluation performed on these quinonoids against a broad panel of drug‐resistant and drug‐sensitive clinical isolates, to the best of our knowledge. Copyright © 2013 John Wiley & Sons, Ltd.